Nektar(US:NKTR) Seeking Alpha·2025-12-16 18:29Core Viewpoint - Nektar Therapeutics is hosting an Analyst and Investor event to discuss the top line results of their RESOLVE-AA study, focusing on the potential of their therapy rezpegaldesleukin and future development plans [1][2]. Group 1: Company Overview - The event features key executives including Howard Robin (President and CEO), Dr. Jonathan Zalevsky (Chief Research and Development Officer), and Dr. Mary Tagliaferri (Chief Medical Officer) [2]. - A panel of key opinion leaders in dermatology and alopecia areata will participate in the Q&A session, including Dr. Jonathan Silverberg, Dr. David Rosmarin, and Dr. Benjamin Ungar [2]. Group 2: Future Outlook - The company plans to make forward-looking statements regarding the therapy potential of rezpegaldesleukin, future clinical data presentations, and overall business development [3].